Note: Arsenal Biosciences's revenues are gauged from an analysis of company filings.
Arsenal Biosciences's Income Statement (based on Industry Averages)
Arsenal Biosciences P&L
$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit
Investor Activity
Arsenal Biosciences has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
September 9, 2022
9
100%
$33 MM
Complete list of funding rounds and total amounts in the Company Report
Trademark Applications
Trademark applications show the products and services that Arsenal Biosciences is developing and marketing.
Arsenal Biosciences doesn't have any recent trademark applications, indicating Arsenal Biosciences is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
ARSENALBIO Biologics for medical use, namely, biological preparations for the assessment of treatment options for, and the treatment and prophylaxis of, solid tumors and oncological diseases, disorders and conditions; biologics for medical use, namely, immune cell therapies and T-cell preparations for the treatment of solid tumors; biologics for medical use, namely, immune cell therapies and T-cell preparations for the treatment of oncological and infectious diseases, disorders and conditions; biologics for medical use, namely, biologics for the assessment of treatment options for solid tumors; biologics for medical use, namely, biologics for the assessment of treatment options for oncological and infectious diseases, disorders and conditions; biologics for medical purposes, namely, biologics for detecting the presence of malignant diseases, disorders and conditions
03/26/2021
A Biologics for medical use, namely, biological preparations for the assessment of treatment options for, and the treatment and prophylaxis of, solid tumors and oncological diseases, disorders and conditions; biologics for medical use, namely, immune cell therapies and T-cell preparations for the treatment of solid tumors; biologics for medical use, namely, immune cell therapies and T-cell preparations for the treatment of oncological and infectious diseases, disorders and conditions; biologics for medical use, namely, biologics for the assessment of treatment options for solid tumors; biologics for medical use, namely, biologics for the assessment of treatment options for oncological and infectious diseases, disorders and conditions; biologics for medical purposes, namely, biologics for detecting the presence of malignant diseases, disorders and conditions
03/26/2021
See all trademarks and details in the Full Report.
Market Share of Arsenal Biosciences's Largest Competitors
A competitive analysis shows these companies are in the same general field as Arsenal Biosciences, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Arsenal Biosciences.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
Future Competition: Arsenal Biosciences's Fastest Growing Competitors
These companies are in the same general field as Arsenal Biosciences and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.